The standard TSH reference range — 0.5 to 4.5 mIU/L — has been the backbone of conventional thyroid diagnosis for decades. But the research behind it is more problematic than most clinicians realize.
The range was derived from the 2002 NHANES III study, which attempted to establish a “healthy” reference population by excluding individuals with known thyroid disease or positive TPO antibodies. The problem? Studies have since shown that up to 20% of Hashimoto’s patients never produce measurable TPO antibodies. This means the NHANES population almost certainly included people with occult thyroid dysfunction — skewing the upper end of the range upward and making the “normal” zone wider than it should be.
When researchers have done a cleaner job of excluding patients with existing thyroid disease, the TSH in a truly healthy population comes out closer to 0.5 to 2.0 mIU/L. The clinical stakes here are real: multiple studies now show that TSH levels in the 3.0–4.5 range — technically within the conventional “normal” — are associated with increased cardiovascular risk, and thyroid hormone replacement in patients with TSH between 2.5 and 4.5 has been shown to improve atherogenic lipid profiles and impaired vascular function.
The functional medicine takeaway: a TSH above 2.0 is a signal to look more carefully — not necessarily to treat, but to investigate. The functional reference range for TSH is 0.5 to 2.0 mIU/L.
Functional Reference Ranges: Additional Thyroid Markers
Where conventional medicine often stops at TSH, a functional medicine thyroid panel includes the full picture: free T3, total T3, free T4, total T4, reverse T3, TPO antibodies, and thyroglobulin antibodies.
Running a TSH alone is like trying to read a sentence with half the words missing. Free T4 and free T3 are better indicators of what’s happening at the cellular level than their total counterparts — and markers like reverse T3 and thyroid antibodies complete the picture in ways a single TSH never can.
Two ranges worth knowing: the functional reference range for TSH sits at 0.5–2.0 mIU/L — meaningfully narrower than the conventional 0.5–4.5 — and free T3 is ideally maintained in the upper half of its reference range. When free T3 is low relative to T4, that conversion gap becomes its own clinical story worth investigating.
Useful adjunct markers include alkaline phosphatase (often low in hypothyroidism and a proxy for immune tolerance), MCV, and urine or hair iodine testing — each of which adds context the serum panel alone won’t give you.
The full functional ranges and how to interpret pattern combinations across the panel are part of what we cover in the Functional Hormone Mastery course through the Kresser Institute.
| Marker | Functional Range |
| TSH | 0.5–2.0 mIU/L |
| Free T4 | 1.0–1.5 ng/dL |
| Free T3 | 2.5–4.0 pg/mL |
Recognizing the Four Core Thyroid Presentations
One of the most clinically valuable skills in thyroid care is pattern recognition — reading the full panel together rather than reacting to a single out-of-range marker. Here are the four presentations every functional medicine practitioner needs to be able to identify and distinguish.
1. Overt Hypothyroidism
The classic picture: elevated TSH with low free T4 and/or free T3. Patients typically present with the familiar constellation of fatigue, cold intolerance, weight changes, brain fog, constipation, and dry skin. This pattern calls for thyroid hormone replacement alongside investigation into underlying root causes — because treating the hormone without addressing what drove the dysfunction in the first place is a recipe for incomplete resolution.
2. Subclinical Hypothyroidism
Defined by elevated TSH with normal thyroid hormone levels, subclinical hypothyroidism has an estimated prevalence of 4.3% in the U.S. adult population — rising to approximately 10% in women over 60. It is frequently undertreated, yet it carries real clinical weight: research shows it may increase cardiovascular disease risk by up to 60%, and affected patients consistently show higher total cholesterol, LDL, and C-reactive protein than euthyroid counterparts.
At the same time, there is a genuine risk of overtreatment. Roughly 20% of patients currently on thyroid replacement are overtreated, with associated risks including atrial fibrillation, reduced bone mineral density, and cardiac dysfunction. The functional medicine approach: address underlying pathology first, retest, and use a validated risk tool to guide decisions about when to initiate replacement.
3. Hashimoto’s Thyroiditis
Hashimoto’s is the cause of hypothyroidism in up to 90% of cases — yet it is routinely missed. The textbook pattern is high TSH, low T3/T4, and elevated TPO antibodies. But the clinical reality is considerably messier.
Because of the relapsing-remitting nature of the autoimmune attack, TSH can oscillate between low, normal, and high. Antibody levels fluctuate between elevated and normal — sometimes across visits with the same patient. A single normal antibody result does not rule out Hashimoto’s. And critically: up to 20% of Hashimoto’s patients never produce measurable TPO antibodies at all, with an additional 13% showing only low-level titers. If we relied solely on serum findings to confirm the diagnosis, we would miss it in at least half of affected patients.
Practical implication: thyroid ultrasound is an essential part of the workup in any patient with a clinical picture consistent with autoimmune thyroid disease — even when antibodies are negative. Ideal diagnostic confidence requires antibody testing on at least three separate occasions, several months apart, combined with ultrasound imaging.
4. Central Hypothyroidism
This presentation breaks the expected pattern and is easy to miss precisely because of it. In central hypothyroidism, TSH is low or normal — not elevated — despite low T4 and T3. The problem lies upstream: insufficient TSH stimulation from the pituitary or hypothalamus, rather than primary thyroid gland failure. Classic causes include pituitary macroadenomas, pituitary surgeries, and post-radiation sequelae. It can also appear in early-stage Hashimoto’s when the immune attack is actively relapsing and transiently suppressing pituitary output.
When you see a low-normal TSH alongside low T4 and T3 — especially with a hypothyroid symptom picture — resist the reflex to call it “normal thyroid.” Confirmation requires a TSH stimulation test and evaluation of other pituitary hormones including growth hormone, LH, FSH, and ACTH.
The Conversion Problem: Why Free T3 Matters More Than You Think
Most circulating thyroid hormone is T4 — the inactive storage form. Cellular activity depends on peripheral conversion of T4 to free T3, the biologically active form. This conversion step is where the clinical picture often quietly breaks down, and it is a key reason why T4 monotherapy alone frequently fails to resolve patient symptoms even when TSH “normalizes.”
Under conditions of physiological, psychological, or inflammatory stress, the body preferentially shunts T4 toward reverse T3 (rT3) — an inactive metabolite that competes with free T3 at the cellular receptor. The result is a patient who looks unremarkable on a standard TSH panel but is functionally hypothyroid at the tissue level.
Factors that impair T4-to-T3 conversion include systemic inflammation, HPA axis dysfunction, GI dysfunction, iron deficiency or overload, nutrient deficiencies (particularly selenium, zinc, and iodine), prolonged fasting or very low calorie intake, low testosterone, and aging.
When you see low free T3 in the presence of normal or elevated T4 — or a high reverse T3 relative to free T3 — the clinical question is not “should we add more T4?” It is “what is driving the conversion impairment?” Addressing the upstream driver will often normalize thyroid markers without requiring hormone replacement at all.
✦ Clinical Pearl 1: Antibody-Negative Does Not Mean Hashimoto’s-Free
Up to 20% of confirmed Hashimoto’s patients never produce measurable TPO antibodies, and an additional 13% show only low-level titers. A single negative antibody result — or even a repeatedly negative result — does not exclude autoimmune thyroid disease. In any patient with a clinical picture consistent with Hashimoto’s (fatigue, brain fog, fluctuating thyroid function, positive family history, postpartum onset), thyroid ultrasound should be part of the workup regardless of antibody status. Ultrasound will reveal the characteristic heterogeneous, hypoechoic texture of autoimmune thyroiditis even when the serum panel is clean. For diagnostic confidence, antibody testing on at least three separate occasions several months apart — combined with ultrasound — is the standard to work toward.
✦ Clinical Pearl 2: The Reverse T3 Ratio Is a Window Into Metabolic Stress
When a patient presents with classic hypothyroid symptoms but a “normal” TSH, look beyond the standard markers. A free T3:reverse T3 ratio below 20 (using pg/mL for both) or a total T3:reverse T3 ratio below 10 is a red flag for impaired conversion — frequently driven by inflammation, HPA axis dysregulation, iron imbalance, or nutrient deficiency rather than primary thyroid failure. The functional medicine advantage here is asking why the conversion is impaired rather than simply supplementing around it. Treating the upstream driver — gut dysfunction, adrenal stress, inflammatory load, nutritional gaps — will often normalize the panel without adding hormone replacement. This is the kind of clinical resolution that keeps patients out of the “my labs are normal but I still feel terrible” cycle.
Want to Go Deeper?
The clinical decision-making behind thyroid assessment — including how to systematically evaluate the root causes of Hashimoto’s, when to consider replacement, and how to interpret complex pattern combinations across the full panel — is covered in depth in the Functional Blood Testing course through the Kresser Institute. If you’re building a practice based off root cause medicine or want to learn more, this is the training that will give you the diagnostic confidence to get there.
Part 2 of this series, covering the functional medicine treatment framework for thyroid hypofunction, from immune modulation to hormone replacement strategy, will be in your inbox soon.
